Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 5045-5045 ◽  
Author(s):  
R. M. Bukowski ◽  
W. M. Stadler ◽  
R. A. Figlin ◽  
J. J. Knox ◽  
N. Gabrail ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
North America ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Safety And Efficacy ◽  
Subset Analysis ◽  
Expanded Access Program ◽  
Access Program

scholarly journals Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Cancer ◽  
2010 ◽  
Vol 116 (5) ◽  
pp. 1272-1280 ◽  
Author(s):  
Walter M. Stadler ◽  
Robert A. Figlin ◽  
David F. McDermott ◽  
Janice P. Dutcher ◽  
Jennifer J. Knox ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
North America ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Safety And Efficacy ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

Oncology ◽  
2010 ◽  
Vol 78 (5-6) ◽  
pp. 340-347 ◽  
Author(s):  
Ronald M. Bukowski ◽  
Walter M. Stadler ◽  
David F. McDermott ◽  
Janice P. Dutcher ◽  
Jennifer J. Knox ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Advanced Renal Cell Carcinoma ◽  
Safety And Efficacy ◽  
Expanded Access ◽  
The North ◽  
Expanded Access Program ◽  
Access Program
Sign in / Sign up

Export Citation Format

Share Document